BidaskClub downgraded shares of Amarin Corporation PLC (NASDAQ:AMRN) from a strong-buy rating to a buy rating in a report released on Friday morning.

A number of other research analysts have also recently commented on AMRN. HC Wainwright reissued a buy rating and set a $10.00 target price on shares of Amarin Corporation PLC in a research report on Wednesday, June 28th. Jefferies Group LLC boosted their target price on shares of Amarin Corporation PLC from $5.00 to $7.00 and gave the stock a buy rating in a research report on Friday, June 30th. Zacks Investment Research raised shares of Amarin Corporation PLC from a hold rating to a buy rating and set a $4.75 target price on the stock in a research report on Tuesday, July 11th. Finally, Cantor Fitzgerald set a $5.00 target price on shares of Amarin Corporation PLC and gave the stock a buy rating in a research report on Monday, June 12th. Six investment analysts have rated the stock with a buy rating, Amarin Corporation PLC currently has an average rating of Buy and an average target price of $7.35.

Shares of Amarin Corporation PLC (AMRN) traded down 1.271% during midday trading on Friday, hitting $3.495. 355,908 shares of the stock were exchanged. The firm’s market cap is $946.08 million. Amarin Corporation PLC has a 12-month low of $2.37 and a 12-month high of $4.47. The firm has a 50 day moving average of $3.75 and a 200 day moving average of $3.29.

Amarin Corporation PLC (NASDAQ:AMRN) last released its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.01. The business had revenue of $34.60 million for the quarter, compared to the consensus estimate of $37.85 million. During the same period in the prior year, the company posted ($0.14) EPS. The firm’s revenue for the quarter was up 35.7% compared to the same quarter last year. Equities analysts forecast that Amarin Corporation PLC will post ($0.23) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at https://www.watchlistnews.com/bidaskclub-lowers-amarin-corporation-plc-nasdaqamrn-to-buy/1465389.html.

In other news, General Counsel Joseph T. Kennedy sold 307,911 shares of the business’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $4.00, for a total transaction of $1,231,644.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 3.72% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN increased its position in Amarin Corporation PLC by 4.8% in the first quarter. Wells Fargo & Company MN now owns 32,801 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 1,500 shares in the last quarter. Perkins Capital Management Inc. acquired a new position in Amarin Corporation PLC during the first quarter worth about $110,000. JPMorgan Chase & Co. increased its position in Amarin Corporation PLC by 27.1% in the first quarter. JPMorgan Chase & Co. now owns 35,590 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 7,580 shares in the last quarter. Private Advisor Group LLC increased its position in Amarin Corporation PLC by 2.1% in the first quarter. Private Advisor Group LLC now owns 50,170 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 1,032 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. increased its position in Amarin Corporation PLC by 1.4% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 143,650 shares of the biopharmaceutical company’s stock worth $460,000 after buying an additional 2,050 shares in the last quarter. 37.55% of the stock is currently owned by hedge funds and other institutional investors.

About Amarin Corporation PLC

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.